Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial.
Jie XuLu XieXin SunKuisheng LiuXin LiangZhenyu CaiXiaodong TangWei GuoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The protracted dx5x2 VIT schedule showed superior efficacy and favorable tolerability compared with the shorter dx5 VIT schedule in patients with relapsed or refractory Ewing sarcoma.